Product Description: MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer[1].
Applications: Cancer-Kinase/protease
Formula: C18H14N4O
References: [1]Ah-Young Kim, et al. MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast cancer. Front Oncol. 2020 Sep 29;10:571601.
CAS Number: 1190277-80-5
Molecular Weight: 302.33
Compound Purity: 98.13
Research Area: Cancer
Solubility: DMSO : 250 mg/mL (ultrasonic)
Target: MASTL